Eli Lilly’s Foundayo Records 1,390 Prescriptions in Launch Week as Oral Obesity Drug Competition Intensifies
Eli Lilly recently rolled out Foundayo within the competitive obesity treatment market. Initial tracking data shows that physicians wrote…
-
-
Comparative Analysis of Oral GLP-1 Receptor Agonists and Subcutaneous Wegovy: Clinical and Economic Considerations
GLP-1 receptor agonists mark an important progress in the field of metabolic medicine. These agents imitate natural incretin hormones…
-
Are GLP-1 Pills Safe Long-Term?
Starting a treatment journey with GLP-1 pills marks a major milestone in managing metabolic health. These medications originally required…
-
Orforglipron Surges Ahead: Eli Lilly’s Oral GLP-1 Pill Beats Oral Semaglutide in Landmark Diabetes Trial
Eli Lilly has unveiled striking results from a head-to-head clinical trial showing its experimental oral GLP-1 pill, Orforglipron, outperformed…
-
Lilly Bets Big on Obesity Pill, Leaving Peptron Deal in Limbo
Eli Lilly and Company is accelerating its push into the fast-growing obesity drug market. However, its renewed focus on…
-
SNAC Under the Microscope: Study Questions Safety of Key Ingredient in Oral Weight-Loss Pills
A new study has placed salcaprozate sodium, known as SNAC, under scientific scrutiny. Researchers warn that this widely used…
-
GLP-1 Weight Loss Pills: The Needle-Free Breakthrough Changing Obesity Care
New GLP-1 weight loss pills are reshaping how doctors treat obesity across the United States. These medications offer patients…
-
Sesame Care Review: Transparent, Affordable Healthcare with Modern Weight-Loss Innovation
Sesame Care is a U.S.-based direct-to-patient healthcare marketplace designed to simplify how individuals access medical services. Founded with the…
-
Wegovy Pill Draws Wave of First-Time Users, Expanding GLP-1 Weight-Loss Market
More than a third of patients who started taking Novo Nordisk’s Wegovy pill had never used a GLP-1 drug…
-
From Needles to Pills: Big Pharma’s High-Stakes Race to Redefine Weight Loss
Pharmaceutical companies are racing to transform weight‑loss treatment. They are shifting from weekly injections to daily pills, opening easier…
